BioLife Solutions, Inc.

NASDAQ:BLFS

Medical - Instruments & Supplies

Healthcare
$38.61 +1.56%

+$0.40 today

Market cap
$1.89B
Beta
1.97
P/E (TTM)
-119.9
EPS (TTM)
-$0.22
52W Low $17.86High $29.62

Volume 4.39M

Average 0.52M

BLFS Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

BioLife Solutions, Inc.NASDAQ: BLFS

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 63.3%

Gross margin was 63.3% in Q1 FY2026, down 2.6 pp from a year earlier. On a trailing-twelve-month basis it was 63.9%, down 19.5 pp year over year. Over 3 fiscal years it widened by 3.0 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
63.3%-4.2 pp QoQ
Last fiscal yearDec 2025
64.6%-0.7 pp YoY
LTMMar 2026
63.9%-19.5 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-2.6 pp——
1 year-0.7 pp——
3 years+3.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
64.6%
Year-over-year change
-0.7pp

Gross Margin vs competitors

How BLFS compares with its peers on the latest reported figures

  • BLFS's LTM Mar 2026 gross margin of 63.9% is the 7th highest of the 11 companies compared; the peer median is 68.0%.
  • Its year-over-year change of -19.5 pp is the lowest of 10, against a peer median of +1.4 pp.
  • Over three fiscal years its change of +3.0 pp compares with a peer median of +3.4 pp.
BLFS Competitors Peer median
Gross Margin for BLFS and competitors
Company Period LTM level YoY 3-year change
STAASTAAR Surgical CompanyLTM Apr 202676.4% +2.4 pp-2.4 pp
ATRCAtriCure, Inc.LTM Jun 202676.2% +1.5 pp-0.0 pp
NVCRNovoCure LimitedLTM Mar 202675.2% -2.0 pp-4.1 pp
HROWHarrow Health, Inc.LTM Mar 202674.1% -0.4 pp+3.7 pp
ESTAEstablishment Labs Holdings Inc.LTM Sep 202670.2% +1.4 pp+3.4 pp
PHRPhreesia, Inc.LTM Apr 202665.8% -2.2 pp+6.8 pp
BLFSBioLife Solutions, Inc.LTM Mar 202663.9% -19.5 pp+3.0 pp
KMTSKestra Medical Technologies, Ltd.LTM Jan 202648.8% +14.6 pp—
NEOGNeogen CorporationLTM Aug 202647.4% +6.3 pp-2.4 pp
AZTAAzenta, Inc.LTM Sep 202644.2% -2.0 pp+9.2 pp
PLSEPulse Biosciences, Inc.LTM Jun 2026-21.6% —+1246.3 pp
Peer median (excluding BLFS) 68.0%+1.4 pp+3.4 pp

Competitors are the stored peer set for BLFS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue119.16M76.24M75.86M82.25M96.21M
Cost of Revenue90.31M29.33M96.52M28.58M34.1M
Gross Profit28.85M46.91M46.75M53.67M62.12M
Gross Margin24.2%61.5%61.6%65.3%64.6%
Research & Development11.82M14.8M18.8M7.91M7.57M
Selling, General & Admin48.09M44.93M55.97M50.15M55.37M
Operating Expenses73.34M52.83M117.58M60.8M74.25M
Depreciation & Amortization12.87M19.96M12.3M8.66M4.69M
EBITDA(16.65M)(124.18M)(45.24M)1.53M3.61M
EBITDA Margin-14.0%-162.9%-59.6%1.9%3.7%
Operating Income(35.16M)(5.92M)(23.44M)(7.13M)(1.08M)
Operating Margin-29.5%-7.8%-30.9%-8.7%-1.1%
Interest Income00000
Interest Expense485K687K1.81M719K2.71M
Other Income / Expenses6.13M1.08M4.97M(4.3M)(11M)
Income Before Tax(29.03M)(4.85M)(18.47M)(11.43M)(12.08M)
Pre-Tax Margin-24.4%-6.4%-24.4%-13.9%-12.6%
Income Tax Expense(20.12M)(5.24M)24K(38K)49K
Net Income(8.91M)(139.81M)(66.43M)(20.18M)(12.13M)
Net Margin-7.5%-183.4%-87.6%-24.5%-12.6%
EPS (Basic)(0.23)(3.29)(1.52)(0.44)(0.25)
EPS (Diluted)(0.23)(3.29)(1.52)(0.44)(0.25)
Weighted Avg Shares38.5M42.48M43.72M46.07M47.75M
Weighted Avg Shares (Diluted)38.5M42.48M43.72M46.07M48.65M

BioLife Solutions, Inc.

NASDAQ:BLFS

Intrinsic Alpha fair value

Locked

Current Price

$38.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.